Last reviewed · How we verify
NCT06809426
Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer
NA trial testing 177Lu-LNC1011 in PSMA PET-Positive Castration-Resistant Prostate Cancer in 13 participants. Completed in 24 October 2024.
14 October 2024
Quick facts
| Lead sponsor | Affiliated Hospital of Jiangnan University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 13 |
| Start date | 21 August 2023 |
| Primary completion | 14 October 2024 |
| Estimated completion | 24 October 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- 177Lu-LNC1011 — full drug profile →
Conditions studied
- PSMA PET-Positive Castration-Resistant Prostate Cancer — all drugs for PSMA PET-Positive Castration-Resistant Prostate Cancer →
Sponsor
Affiliated Hospital of Jiangnan University
Who can join
18 and older, male only, with PSMA PET-Positive Castration-Resistant Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Evaluating the safety and antitumor efficacy of 177Lu-LNC1011
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
PSMA-targeted radioligand therapy with [<sup>177</sup>Lu]Lu-LNC1011 for metastatic castration-resistant prostate cancer: a pilot study.
Hou L, Wang Y, Fu H, Chen L, et al · · 2025 · cited 1× · PMID 40208314 · DOI 10.1007/s00259-025-07245-8
Verify or expand the search:
- PubMed search for NCT06809426
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of 177Lu-LNC1011
Trials testing the same drug.
- NCT06250244 — 177Lu-LNC1011 in Patients with Metastatic Castration-resistant Prostate Cancer · Phase 1, PHASE2 · unknown
Other recruiting trials for PSMA PET-Positive Castration-Resistant Prostate Cancer
Currently open trials in the same condition.
- NCT06850545 — Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer · recruiting
Other Affiliated Hospital of Jiangnan University trials
Trials by the same sponsor.
- NCT07023861 — The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies · EARLY_PHASE1 · enrolling by invitation
- NCT07023848 — PET Image Exploration of 89Zr-labeled Antibody Fragments Targeting HER2 in Patients With Malignant Tumors · EARLY_PHASE1 · enrolling by invitation
- NCT07162779 — Evaluation of [68Ga]DOTA-IR-780-C-4 in PET Imaging Studies for PSMA-Positive Prostate Cancer Patients · NA · enrolling by invitation
- NCT06448975 — An Exploratory Study of Deep Cervical Lymphovenous Bypass (LVB) in Alzheimer's Disease · NA · recruiting
- NCT06723665 — The Exploration of 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients · NA · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06809426 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Affiliated Hospital of Jiangnan University
- Last refreshed: 5 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06809426.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing